Kyowa Kirin International

CompanyUnited Kingdom

Kyowa Kirin International develops one asset. Mostly antibody acting on CCR4; based in the United Kingdom.

1
Asset
Furthest stage
Not known
0
Trials
1
Signal

Pipeline

1
  • mogamulizumab

    Binds CCR4 on malignant T cells and induces antibody-dependent cellular cytotoxicity.

    Stage not known, Antibody, CCR4

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals1

Intelligence